UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 6, 2007
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)
| |
|
|
|
|
| Delaware
|
|
0-26224
|
|
51-0317849 |
| (State or other jurisdiction of
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.) |
| incorporation or organization) |
|
|
|
|
311 Enterprise Drive
Plainsboro, NJ 08536
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (609) 275-0500
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
ITEM 8.01. OTHER EVENTS.
Private Offering
In a press release issued on June 6, 2007, Integra LifeSciences Holdings Corporation (the
“Company”) announced the pricing of its offering of $150 million aggregate principal amount of
senior convertible notes due 2010 and $150 million aggregate principal amount of senior convertible
notes due 2012 (together, the “notes”) in a private placement, subject to market conditions and
other factors. The Company has granted the initial purchasers of the notes options to purchase up
to an additional $15 million aggregate principal amount of each series of notes, in each case
within 13 days of the initial issuance of the notes.
A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by
reference, and is being filed pursuant to Rule 135c under the Securities Act of 1933, as amended.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits.
| |
|
|
| Exhibit Number |
|
Description of Exhibit |
|
|
|
99.1
|
|
Press release issued by Integra LifeSciences Holdings Corporation dated June 6, 2007 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has
duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
| |
|
|
|
|
| |
|
|
| Date: June 6, 2007 |
By: |
/s/ Stuart M. Essig
|
|
| |
|
Stuart M. Essig |
|
| |
|
President and Chief Executive Officer |
|
| |